Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $19.00 Consensus Price Target from Analysts

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) have earned an average rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.00.

Several analysts have issued reports on CTNM shares. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Leerink Partners assumed coverage on shares of Contineum Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada cut their price objective on shares of Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday, November 21st. Finally, Morgan Stanley restated an “equal weight” rating and set a $14.00 target price (down from $23.00) on shares of Contineum Therapeutics in a research note on Thursday, January 8th.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $15.34 on Wednesday. The company has a market cap of $447.62 million, a P/E ratio of -6.82 and a beta of 1.18. Contineum Therapeutics has a one year low of $3.35 and a one year high of $16.33. The business’s 50-day simple moving average is $13.17 and its 200 day simple moving average is $11.78.

Institutional Investors Weigh In On Contineum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new position in shares of Contineum Therapeutics in the 4th quarter valued at approximately $27,906,000. RA Capital Management L.P. bought a new stake in shares of Contineum Therapeutics in the third quarter worth $24,934,000. Baker BROS. Advisors LP raised its holdings in Contineum Therapeutics by 1,729.3% in the fourth quarter. Baker BROS. Advisors LP now owns 1,420,838 shares of the company’s stock valued at $16,240,000 after acquiring an additional 1,343,168 shares in the last quarter. Suvretta Capital Management LLC boosted its stake in Contineum Therapeutics by 65.2% during the 4th quarter. Suvretta Capital Management LLC now owns 2,841,334 shares of the company’s stock valued at $32,476,000 after acquiring an additional 1,121,334 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Contineum Therapeutics during the 3rd quarter valued at $11,178,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.